99 related articles for article (PubMed ID: 631487)
1. Mechanism for reduced drug clearance in patients with cirrhosis.
Pessayre D; Lebrec D; Descatoire V; Peignoux M; Benhamou JP
Gastroenterology; 1978 Mar; 74(3):566-71. PubMed ID: 631487
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurement of effective hepatic blood flow and systemic circulation.
Hashimoto M; Watanabe G
Hepatogastroenterology; 2000; 47(36):1669-74. PubMed ID: 11149029
[TBL] [Abstract][Full Text] [Related]
4. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
[TBL] [Abstract][Full Text] [Related]
5. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
[TBL] [Abstract][Full Text] [Related]
6. [Hepatic blood flow, portal hypertension and liver failure in patients with alcoholic cirrhosis (author's transl)].
Lebrec D; Sicot C; Benhamou JP
Arch Fr Mal App Dig; 1973 Sep; 62(6):465-71. PubMed ID: 4779228
[No Abstract] [Full Text] [Related]
7. Indocyanine green clearance following single and chronic cimetidine doses.
MacKichan JJ; Schaal SF; Stine RA; Boudoulas H
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):323-6. PubMed ID: 6739959
[TBL] [Abstract][Full Text] [Related]
8. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis.
Merkel C; Gatta A; Caregaro L; Sacerdoti D; Rondana M; Ruol A
Scand J Clin Lab Invest; 1987 Nov; 47(7):667-72. PubMed ID: 2891182
[TBL] [Abstract][Full Text] [Related]
10. Verapamil pharmacokinetics and liver function in patients with cirrhosis.
Finucci GF; Padrini R; Piovan D; Melica E; Merkel C; Gatta A; Zuin R
Int J Clin Pharmacol Res; 1988; 8(2):123-6. PubMed ID: 3378854
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
Saudek F; Morávek J; Modr Z
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
[TBL] [Abstract][Full Text] [Related]
12. Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol.
Niemann CU; Henthorn TK; Krejcie TC; Shanks CA; Enders-Klein C; Avram MJ
Clin Pharmacol Ther; 2000 Apr; 67(4):342-50. PubMed ID: 10801242
[TBL] [Abstract][Full Text] [Related]
13. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.
Le Couteur DG; Hickey H; Harvey PJ; Gready J; McLean AJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1553-8. PubMed ID: 10336552
[TBL] [Abstract][Full Text] [Related]
14. Functional and non-functional liver blood flow in patients with liver cirrhosis measured by indocyanine green.
Perlik F; Janku I; Jedlicka J
Methods Find Exp Clin Pharmacol; 1992; 14(6):459-64. PubMed ID: 1469955
[TBL] [Abstract][Full Text] [Related]
15. [Determination of hepatic blood flow in chronic liver diseases using the constant infusion technic].
Vorobioff J; Carnovale C; Topol R; Picabea E; Villavicencio R; Tanno H; Audano M; Audano G
Acta Gastroenterol Latinoam; 1984; 14(3):229-34. PubMed ID: 6537116
[TBL] [Abstract][Full Text] [Related]
16. Normal metabolism of morphine in cirrhosis.
Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
[TBL] [Abstract][Full Text] [Related]
17. Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis.
Merkel C; Bianco S; Bolognesi M; Caregaro L; Amodio P; Sacerdoti D; Gatta A
Am J Gastroenterol; 1992 Nov; 87(11):1580-6. PubMed ID: 1442677
[TBL] [Abstract][Full Text] [Related]
18. Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.
Semenowicz-Siuda K; Markiewicz A; Korczyńska-Wardecka J
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):653-8. PubMed ID: 6526540
[TBL] [Abstract][Full Text] [Related]
19. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
20. Effects of anesthetic agents and abdominal surgery on liver blood flow.
Cowan RE; Jackson BT; Grainger SL; Thompson RP
Hepatology; 1991 Dec; 14(6):1161-6. PubMed ID: 1959866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
